Biostage Inc (NASDAQ:BSTG) was downgraded by investment analysts at Maxim Group from a “buy” rating to a “hold” rating in a report issued on Thursday.

Biostage (NASDAQ:BSTG) opened at 0.85 on Thursday. The firm has a 50-day moving average price of $0.93 and a 200 day moving average price of $1.19. The firm’s market capitalization is $14.54 million. Biostage has a one year low of $0.73 and a one year high of $3.47.

Biostage (NASDAQ:BSTG) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.07. The business had revenue of $26 million for the quarter. Analysts anticipate that Biostage will post ($0.86) EPS for the current fiscal year.

Biostage Company Profile

Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

5 Day Chart for NASDAQ:BSTG

Receive News & Stock Ratings for Biostage Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc and related stocks with our FREE daily email newsletter.